Welcome To The Nventa Biopharmaceuticals Corp HUB On AGORACOM

Developing innovative therapeutics for the treatment of viral infections and cancer

Message: anyone

Re: anyone

in response to by
posted on Sep 16, 2008 11:53AM

I have held this stock for a number years through 2 name changes.The thesis is that the adjuvant for the vaccine is revolutionary. Who knows but they had a good phase 1 trial and they are looking for funding for a phase 2. (multicentered) They have good people supporting it so it is definitely worth a gamble.


New Message
Please login to post a reply